Matthew Goetz

Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer. Co-authored by @GraceChoongMD, @DrJudyBoughey, and @mpgoetz #BreastCancer #bcsm Read more. brnw.ch/21wS1Ws

@rleonferre @mpgoetz @MayoClinic @MayoCancerCare @MayoHemeOnc @oncodaily @OncBrothers @OncLive @IMG_Oncologists @StoriesImg #breastcancer #twincities Excellent line up of speakers; MInnesota, plz register for the presentation next week- April 10.

The ki-67 response rate (4 week Ki<=10%) was 86% in 22 patients. We are now ready to move this to the randomized portion comparing endoxifen with AI+ OFS

Excited to present the initial findings of the pk run-in of neoadjuvant Z-endoxifen in premenopausal women at the annual SABCS meeting

Congratulations to Dr. Roberto Leon Ferre for your ASCO Conquer Cancer Advanced Clinical Research Award.

Bottom line, ET omission in this group is associated with a 25% increased risk of death with a median follow-up of 3 years.

What is the impact of endocrine therapy omission in ER low (IHC 1-10%) breast cancer? Dr. Grace Choong presents data at ASCO 2024 regarding the detrimental impact of ET omission in this group of pts with tumors traditionally characterized as biologically similar to TNBC

📣What is the role of immune activation on the prognosis of early #TNBC if chemo is not given? We evaluated ~ 2,000 pts w eTNBC from 13 institutions around the globe to answer this. See our results published today in @JAMA_current jamanetwork.com/journals/jama/…

IT’S GREAT TO BE A MICHIGAN WOLVERINE! #GoBlue

@CFBONFOX @UW_Football @UMichFootball Michigan

Who do you think has better uniforms: @UW_Football or @UMichFootball? 🔥

In premenopausal women with ER+/HER2- breast cancer, the neoadjuvant EVANGELINE trial is testing the hypothesis that dual targeting of ER and PKC beta will result in substantial anti tumor activity without the need for ovarian function suppression evangelinetrial.com

Endoxifen is known to be a more potent inhibitor of ER alpha compared to tamoxifen.  Based on an unbiased proteomic screen, we identify protein kinase beta as a new endoxifen drug target, resulting in suppression of AKT signaling and apoptosis pubmed.ncbi.nlm.nih.gov/38114522/

@DrSGraff @OncoAlert @drsarahsam @StoverLab @ErikaHamilton9 @hoperugo @Annals_Oncology Look out SERDS. SERMS are making a comeback!

Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial - Annals of Oncology annalsofoncology.org/article/S0923-… @OncoAlert @mpgoetz @drsarahsam @StoverLab @ErikaHamilton9 @hoperugo @Annals_Oncology

@CarlosArteagaMD @utswcancer Well done!

Just finished #46, arguably the best #SABCS I can think of. Still at the forefront of breast cancer clinical & translational research. Plus excellent representation by Simmons Cancer Center members! #SABCS23 @utswcancer

Jack Cuzick shows the benefit of anastrozole in IBIS -II according to baseline estradiol levels at the SABCS McGuire lecture. Potentially practice changing.

@ALLIANCE_org plenary session. New group chair Dr Eva Galanis @MayoCancerCare opens the plenary session.

@UChicagoHemOnc @DrSGraff @RitaNandaMD @DorisDukeFdn @UChicagoMed Rita: Congratulations!

A huge congratulations to our own Dr. Nanda who won the Doris Duke Foundation Paragon Award for Research Excellence! A spectacular tribute to the immense impact you make @RitaNandaMD!!! @DorisDukeFdn @UChicagoMed #AtTheForefront #ResearchExcellence

It was a pleasure to present these data. Critically important, as any biomarker needs to be fully validated before being used to select patients. In this case, these biomarkers are prognostic but clearly not predictive of abemacicib benefit.